Palosuran  ≥98%(HPLC)

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

库存{{model.attbuying.number}}
包装规格:5mg 10mg 25mg 50mg 100mg in glass bottle
溶解性:溶于DMSO(≥30mg/mL)
产品描述:基本信息 产品编号: P10394 产品名称: Palosuran CAS: 540769-28-6   储存条件 粉末 -20℃ 四年     分子式: C25H30N4O2 溶于液体 -80℃ 6个月 分子量: 418.54 -20℃ 1个月 化学名:  1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea Solubility (25°C):   体外:   DMSO   Ethanol   Water   体内(现配现用):   <1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 2.3893mL 11.9466mL 23.8932mL 5mM 0.4779mL 2.3893mL 4.7786mL 10mM 0.2389mL 1.1947mL 2.3893mL   生物活性 产品描述 一种尾加压素II受体拮抗剂。 靶点 3.6 nM (human urotensin II receptor)   体外研究 Palosuran (8h) inhibits 125I-U-II binding to human UT receptor,with IC50s of 46.2nM on TE 671 cells and 86nM on recombinant CHO cells.Palosuran inhibits Ca2+mobilization in response to human U-II in CHO cells expressing human and rat UT receptor with IC50s of 17 and>10000nM,respectively.Palosuran (0.12-10000nM;20 min) inhibits human U-II induced MAPK phosphorylation in a dose-dependent manner in recombinant CHO cells,with an IC50 of 150nM.Phentolamine (1mg/kg;i.v.) produces hypotension and tachycardia in rats. 体内研究 ACT-058362 (10mg/kg/h;i.v.) fully prevents the decrease in renal blood flow after ischemia in rats without decreasing blood pressure.Palosuran (300mg/kg/d;p.o.for 16 weeks) improves the survival,increases insulin,and slows the increase in glycemia,glycosylated hemoglobin,and serum lipids in streptozotocin-induced diabetic rats. Animal Model: Male Wistar rats with renal ischemia and reperfusion Dosage: 20mg/kg/h for 135 min Administration: I.v.(continuous infusion) for 135 min Result: Restored renal blood flow to baseline values at 30 min after reperfusion and by 60 min increased renal blood flow by 12% above baseline values.Did not significantly alter mean arterial blood pressure (MAP) and heart rate (HR).
保存条件:-20℃